Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Bavarian Nordic (BVNRY : OTC)

• Company Description    Bavarian Nordic A/S is a biotechnology company. It focused on the development, manufacturing and commercialization of cancer immunotherapies and vaccines for infectious diseases. The company's product pipeline consists of IMVAMUNE(R), PROSTVAC (R), MVA-BN Brachyury, CV-301, MVA-BN Filo which are in clinical trial stage. Bavarian Nordic A/S is headquartered in Kvistgaard, Denmark. Number of Employees: 759

• Price / Volume Information    Yesterday's Closing Price: $11.22 Daily Weekly Monthly 20 Day Moving Average: 6,644 shares Shares Outstanding: 211.42 (millions) Market Capitalization: $2,372.12 (millions) Beta: 1.40 52 Week High: $19.25 52 Week Low: $5.85 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week 52.65% 71.92% 12 Week 17.73% 29.42% Year To Date -16.58% -1.62%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL Philip Heymans Alle 3 - Hellerup,G7 2900 DNK ph: 45-3326-8383 fax: 45-3326-8380 investor@bavarian-nordic.com http://www.bavarian-nordic.com

• General Corporate Information    Officers Paul Chaplin - Chief Executive Officer and President Gerard van Odijk - Chairman Henrik Birk - Chief Operating Office and Executive Vice Presiden Henrik Juuel - Chief Financial Officer and Executive Vice Preside Frank Verwiel - Director Peer Information Bavarian Nordic (CORR.) Bavarian Nordic (RSPI) Bavarian Nordic (CGXP) Bavarian Nordic (BGEN) Bavarian Nordic (GTBP) Bavarian Nordic (RGRX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 071771109 SIC: 2836 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/22 Next Expected EPS Date: 08/24/22 Share - Related Items Shares Outstanding: 211.42 Most Recent Split Date: (:1) Beta: 1.40 Market Capitalization: $2,372.12 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.22 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-1.07 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 2.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/24/22

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 2.02 Price/Cash Flow: - Price / Sales: 8.75 EPS Growth vs. Year Ago Period: -81.82% vs. Previous Quarter: -150.00% Sales Growth vs. Year Ago Period: -44.37% vs. Previous Quarter: -42.30% ROE 03/31/22 - - 12/31/21 - - 09/30/21 - - ROA 03/31/22 - - 12/31/21 - - 09/30/21 - - Current Ratio 03/31/22 - - 12/31/21 - 2.49 09/30/21 - - Quick Ratio 03/31/22 - - 12/31/21 - 2.24 09/30/21 - - Operating Margin 03/31/22 - - 12/31/21 - - 09/30/21 - - Net Margin 03/31/22 - - 12/31/21 - - 09/30/21 - - Pre-Tax Margin 03/31/22 - - 12/31/21 - -23.94 09/30/21 - - Book Value 03/31/22 - - 12/31/21 - 5.55 09/30/21 - - Inventory Turnover 03/31/22 - - 12/31/21 - 2.31 09/30/21 - - Debt-to-Equity 03/31/22 - - 12/31/21 - 0.00 09/30/21 - - Debt-to-Capital 03/31/22 - - 12/31/21 - 0.26 09/30/21 - -

Powered by Zacks Investment Research ©